As Rosiglitazone Review Looms, FDA Documents Slam RECORD and Find Significant Risks for the Drug

PharmaTimes -- Staffers at the US Food and Drug Administration are divided as to what action, if any, should be taken on GlaxoSmithKline’s Avandia ahead of an eagerly-anticipated advisory committee meeting concerning the diabetes drug this week.